Relmada Therapeutics announced the appointment of Cedric O’Gorman MD as the company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support of the company’s late-stage REL-1017 development program. Dr. O’Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise in the CNS therapeutics field. Most recently, he served as Chief Medical Officer at Alpha Cognition, where he led clinical development programs for the company’s Alzheimer’s disease targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLMD:
- Relmada Therapeutics price target lowered to $4 from $7 at Truist
- Relmada Therapeutics’ REL-1017 in depressive disorder did not reach endpoint
- Relmada Therapeutics call volume above normal and directionally bullish
- Relmada ‘still has a chance’ for positive depression data, says SVB
- Relmada Therapeutics reports Q3 EPS ($1.31), consensus ($1.45)